These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1433752)

  • 1. From the Centers for Disease Control and Prevention. Committee on immunization practices: PedvaxHIB lots with questionable immunogenicity.
    JAMA; 1992 Dec; 268(22):3186. PubMed ID: 1433752
    [No Abstract]   [Full Text] [Related]  

  • 2. Advisory Committee on Immunization Practices update: report of PedvaxHIB lots with questionable immunogenicity.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1992 Nov; 41(46):878-9. PubMed ID: 1435679
    [No Abstract]   [Full Text] [Related]  

  • 3. Immune response of young children vaccinated with Haemophilus influenzae type b conjugate vaccines.
    Madore DV; Phipps DC; Eby R; Johnson CL; Smith DH
    Contrib Microbiol Immunol; 1989; 10():125-50. PubMed ID: 2684505
    [No Abstract]   [Full Text] [Related]  

  • 4. An enzyme-linked immunosorbent assay for quantitation of Haemophilus Influenzae type b polysaccharide-specific IgG1 and IgG2 in human and infant rhesus monkey sera.
    Dolan KT; Staub JM; Schofield TL; Ahonkhai VI; Ellis RW; Vella PP
    J Immunoassay; 1991; 12(4):543-64. PubMed ID: 1806588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opsonophagocidal activity in sera from infants and children immunized with Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate).
    Gray BM
    Pediatrics; 1990 Apr; 85(4 Pt 2):694-7. PubMed ID: 2107521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statement on Haemophilus influenzae type b conjugate vaccines for use in infants and children.
    CMAJ; 1993 Jan; 148(2):199-214. PubMed ID: 8452591
    [No Abstract]   [Full Text] [Related]  

  • 7. Biological activity of Hib conjugates.
    Vella PP; Staub JM; Ellis RW
    Vaccine; 1991 Jun; 9 Suppl():S26-9; discussion S42-3. PubMed ID: 1891953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and reactogenicity of Haemophilus influenzae type b-meningococcus group B outer membrane protein conjugate vaccine in children 2-60 months of age.
    Shehab ZM; Azimi P; Asmar BI; Dunphy MG; Ayoub EM; Dajani AS
    Scand J Infect Dis; 1991; 23(6):763-9. PubMed ID: 1815340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB): clinical evaluation.
    Ahonkhai VI; Lukacs LJ; Jonas LC; Matthews H; Vella PP; Ellis RW; Staub JM; Dolan KT; Rusk CM; Calandra GB
    Pediatrics; 1990 Apr; 85(4 Pt 2):676-81. PubMed ID: 2107518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemophilus influenzae type B conjugate vaccines.
    Kaplan SL
    Pediatr Ann; 1990 Dec; 19(12):712-3, 716-8. PubMed ID: 2280990
    [No Abstract]   [Full Text] [Related]  

  • 11. Dose-related immunogenicity of Haemophilus influenzae type b capsular polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine.
    Wong VK; Quagliata R; Adler R; Kim KS
    Am J Dis Child; 1991 Jul; 145(7):742-5. PubMed ID: 2058604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Background and indications for Haemophilus influenzae type b vaccines consisting of capsular antigen coupled to protein carriers.
    Anderson PW; Stein EC; Insel RA
    Contrib Microbiol Immunol; 1989; 10():115-24. PubMed ID: 2684504
    [No Abstract]   [Full Text] [Related]  

  • 13. Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants.
    Anderson EL; Decker MD; Englund JA; Edwards KM; Anderson P; McInnes P; Belshe RB
    JAMA; 1995 Mar; 273(11):849-53. PubMed ID: 7869554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High antibody responses to booster doses of either Haemophilus influenzae capsular polysaccharide or conjugate vaccine after primary immunization with conjugate vaccines.
    Käyhty H; Eskola J; Peltola H; Saarinen L; Mäkelä PH
    J Infect Dis; 1992 Jun; 165 Suppl 1():S165-6. PubMed ID: 1588156
    [No Abstract]   [Full Text] [Related]  

  • 15. New considerations for Haemophilus influenzae type b vaccination.
    Pinson JB; Weart CW
    Clin Pharm; 1992 Apr; 11(4):332-6. PubMed ID: 1563228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group.
    Schlesinger Y; Granoff DM
    JAMA; 1992 Mar; 267(11):1489-94. PubMed ID: 1538539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with PedvaxHIB, a conjugate vaccine of Haemophilus influenzae type b polysaccharide--Neisseria meningitidis outer membrane protein.
    Ahonkhai VI; Lukacs LJ; Jonas LC; Calandra GB
    Vaccine; 1991 Jun; 9 Suppl():S38-41; discussion S42-3. PubMed ID: 1891956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AAFP recommendations: new Haemophilus influenzae type b immunization schedule. The Commission on Public Health and Scientific Affairs.
    Am Fam Physician; 1991 Apr; 43(4):1437-40. PubMed ID: 2008824
    [No Abstract]   [Full Text] [Related]  

  • 19. National Advisory Committee on Immunization (NACI). Statement on Haemophilus influenzae type B conjugate vaccines for use in infants and children.
    Can Commun Dis Rep; 1992 Dec; 18(23):169-76. PubMed ID: 1291012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin deficiency and idiotype expression in children developing Haemophilus influenzae type b disease after vaccination with conjugate vaccine. The Collaborative Study Group.
    Holmes SJ; Lucas AH; Osterholm MT; Froeschle JE; Granoff DM
    JAMA; 1991 Oct; 266(14):1960-5. PubMed ID: 1895474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.